DogYears - Follistatin

Upcoming

Aging

We are developing a new gene therapy to help our canine companions stay stronger, move more comfortably, and enjoy healthier lives as they age. By supporting muscle growth, easing pain, and calming inflammation linked to arthritis, our follistatin therapy aims to improve everyday mobility and overall wellbeing.

$DYFST

Community Sentiment

How do you feel about DogYears - Follistatin?

...

No trend data

Updates

Feed

View @dogyearsdao on X

Project

Market Overview

180 Million

Canines experiencing arthritis globally

$18 Billion

US companion animal pharmaceutical market

Canine longevity treatment with conditional FDA approval

Additional Documentation

Pitch Deck

Summary

Dog Years DAO is creating a breakthrough therapy to help dogs and people live longer, healthier lives by reducing muscle loss, pain, and inflammation caused by aging and arthritis.

Problem

This project tackles muscle loss from aging and pain caused by arthritis in dogs, aiming to improve their mobility, comfort, and quality of life as they grow older.

Impact

Unlocking healthier, longer lives for dogs and humans, this project pioneers DeSci drug development—combining biotech, crypto, and on-chain data to advance therapies that fight aging, pain, and inflammation.

Market Overview

180 Million

Canines experiencing arthritis globally

$18 Billion

US companion animal pharmaceutical market

Canine longevity treatment with conditional FDA approval

Additional Documentation

Pitch Deck

Summary

Dog Years DAO is creating a breakthrough therapy to help dogs and people live longer, healthier lives by reducing muscle loss, pain, and inflammation caused by aging and arthritis.

Problem

This project tackles muscle loss from aging and pain caused by arthritis in dogs, aiming to improve their mobility, comfort, and quality of life as they grow older.

Impact

Tristan Roberts

A notable biohacker and DeSci evangelist, his work on a HIV gene therapy was covered in Netflix's Unnatural Selection. He co-founded the gene therapy company Minicircle, overseeing their clinical trial in Prospera, after working in the DAO/LLC space.

Emmanuel Harel Bijaoui

Emmanuel Bijaoui is the founder and CEO of Treat, a decentralized contract research organization (CRO) revolutionizing clinical trials in pet health. He previously worked as a dementia researcher and led bioinformatics at a human microbiome startup.

Brandy Nunez

A veterinary practicioner and analog astronaut, Brandy practices outside of LA. She is excited to see if this treatment can help the older dogs she sees, and if the first treatment might help astronauts as well.

Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates

https://www.science.org/doi/abs/10.1126/scitranslmed.3000112

Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat diet–induced obesity

https://www.science.org/doi/full/10.1126/sciadv.aaz7492

This biohacking company is using a crypto city to test controversial gene therapies

https://www.technologyreview.com/2023/02/13/1068330/minicircle-prospera-honduras-biohacking-follistatin-gene-therapy/

Healthy ageing and the science of longevity in dogs

https://www.magonlinelibrary.com/doi/abs/10.12968/coan.2018.23.9.514

Follistatin Alleviates Synovitis and Articular Cartilage Degeneration Induced by Carrageenan

https://onlinelibrary.wiley.com/doi/10.1155/2014/959271

Follistatin | Minicircle

https://minicircle.io/fstpreprint

Tokenomics

10,000,000

Total Supply

Ignition Sale	10%
Wide Liquidity	22.5%
Concentrated Liquidity	15%
Team	10%
Dog Years Inc.	15%
Treasury	20%
Bio Protocol Call Option	2.5%
veBIO Airdrop	5%

10,000,000

Total Supply

Ignition Sale	10%
Wide Liquidity	22.5%
Concentrated Liquidity	15%
Team	10%
Dog Years Inc.	15%
Treasury	20%
Bio Protocol Call Option	2.5%
veBIO Airdrop	5%

Stay up to date

Get the latest community updates and find out about upcoming DogYears - Follistatin developments